Oxford Cancer Biomarkers (OCB) develops and commercialises biomarker tests that enable better informed treatment decisions. Using our biomarker tests provides more effective treatment for patients and economic savings for the healthcare system.
OCB spun out of Oxford University in 2012 from the laboratories of Nick LaThangue (Professor of Cancer Biology) and David Kerr (Professor of Cancer Medicine) to advance personalised medicine for oncology. The company is closely affiliated with the Institute of Cancer Medicine, where its founders lead research groups focused on translational cancer science.
Conveniently located in the Magdalen Centre at the Oxford Science Park we have an effective development team consisting of industry professionals, postdoctoral scientists and oncologists. The experience of the OCB team allows planning from biomarker discovery to adoption into clinical guidelines.
In addition to developing tests for colorectal cancer OCB also works in partnership with pharmaceutical companies to develop companion diagnostic biomarker tests for pipeline drugs in all stages of development.
Nick is a founder of OCB and Professor of Cancer Biology at the University of Oxford. He is a Fellow of the Royal Society of Edinburgh, a Member of the European Molecular Biology Organisation (EMBO), a Fellow of the Academy of Medical Sciences, a Fellow of the Lister Institute and Professorial Fellow at Linacre College Oxford. Nick has founded several companies, including Prolifix and Celleron Therapeutics, and more recently Oxford Cancer Biomarkers, and has considerable experience derived from the biotechnology and pharmaceutical sectors. He served as Chief Business Development Officer and Chief Scientific Officer of TopoTarget, and engineered the IPO on the Scandinavian Stock Exchange.
David is a founder of OCB and Professor of Cancer Medicine at the University of Oxford, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. David has an international reputation for the treatment of, and research into, cjolorectal cancer and the quality of his work has been recognised by the award of several international prizes and the first NHS Nye-Bevan award for innovation.
David has made a significant contribution to reforming the NHS as a Founding Commissioner for Health Improvement, Chair of the National Cancer Services Collaborative, instigator of the Department of Health’s networked approach to clinical cancer research and he developed a 20 year plan for the future of the NHS in Scotland, the “Kerr Report”. David was elected Fellow of the Academy of Medical Sciences in 2000, Honorary Fellow of Royal College of General Practitioners in 2007, appointed Commander of the British Empire in 2002 and was elected President of the European Society of Medical Oncology in 2010.
Currently, David is chairman of TranScrip Partners LLP, base4innovation Ltd and Kirkstall Limited and was previously chairman of BioAnaLab Ltd and a non-executive director of Cobra Biologics plc. Until 2005, David was CEO of Xenova Group plc, a LSE and NASDAQ listed oncology-focussed drug discovery and development company. Prior to joining Xenova, David was President of Syva Company, a medical diagnostics business based in San Jose, California. Earlier, David worked for ICI Pharmaceuticals (now AstraZeneca), during which time he oversaw the launch of Cellmark Diagnostics and its identity and forensic testing business ”DNA Fingerprinting”, and, for 14 years, he worked for Boehringer Mannheim GmBH (now part of Roche) in Europe and the Far East. David is an Honorary Fellow of Brunel University, a previous member of the Emerging Enterprise Council of EuropaBio and of the Bioscience Leadership Council until 2004. David chaired the European Working Group of the Bioscience Innovation and Growth Team charged with setting out a 10 year agenda for developing the UK’s bioscience industry.
Matthew Frohn is a partner at Longwall Venture Partners LLP. Longwall manages two funds and invests in innovative, UK based, early stage companies in the healthcare, science and engineering sectors. Matthew has a DPhil in Biochemistry from Oxford University.
Dean Slagel has 23 years of biopharmaceutical industry and venture investing experience and an MBA from ENPC Business School, Paris. After a global marketing management position at Tillotts Pharma, he spent 10 years with Ferring in global operations and global business development management. He has led Esperante since 2004, building an investment portfolio of up to 21 companies across North America and Europe. During this period, Esperante completed two successful exits (Thiakis and Pinnacle Biologics) and an IPO (Cara). In addition to OCB, Mr Slagel is currently a Board Director of Altacor, Atox Bio, Cara Therapeutics, Canbex Therapeutics and Haemostatix.
Alasdair Macdonald graduated LLB and DipLP Univ of Aberdeen (1980, ‘81), Solicitor Scotland (1982) and England & Wales (1993), Univ of Bristol PG Dip Public Law (modules in Medical Law and Public Health). Alasdair practised litigation in the Edinburgh area before joining the legal Department of Syntex Pharmaceuticals in 1992 then became a Company/Commercial partner in Malkins, Solicitors, London in 1997. He has been in house in the pharmaceuticals sector since 1999 and Head of the European Legal Department of Quintiles since 2000, and is a director of their UK and European subsidiaries.
Academic positions at Aberdeen University followed by 23 years in the pharmaceutical industry. Led development of three major medicines. 7 years at Imperial College London with senior roles in strategic planning, project management and technology transfer. Adjunct Professor at Imperial College Business School. Expertise in healthcare sector and general management. Director of OBS Medical Ltd, Chronos Therapeutics Ltd and Oxtex Ltd. Member of Investment Advisory Board of Oxford Spinout Equity Management.
© Copyright 2017 Oxford Cancer Biomarkers. All Rights Reserved.